Bosutinib. Chronic myeloid leukaemia in treatment failure: major toxicity.
Retrospective analysis of data on 52 patients in whom other tyrosine kinase inhibitors had failed or were poorly tolerated. Beware of frequent and often serious adverse effects with bosutinib, including diarrhoea and hepatotoxicity.